Mark J. Enyedy - 04 Feb 2022 Form 4 Insider Report for ImmunoGen, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Renee Lentini, attorney in fact
Issuer symbol
N/A
Transactions as of
04 Feb 2022
Net transactions value
+$5,852,000
Form type
4
Filing time
08 Feb 2022, 16:34:17 UTC
Previous filing
02 Jul 2021
Next filing
27 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (right to buy) Award $5,852,000 +1,100,000 $5.32 1,100,000 04 Feb 2022 Common Stock 1,100,000 $5.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.